Protein kinase C beta mediates CD40 ligand-induced adhesion of monocytes to endothelial cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Wu Z;Wu Z;Wu Z; Zhao G; Peng L; Du J; Wang S; Huang Y; Ou J; Jian Z
  • Source:
    PloS one [PLoS One] 2013 Sep 09; Vol. 8 (9), pp. e72593. Date of Electronic Publication: 2013 Sep 09 (Print Publication: 2013).
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      CD40 Ligand/*physiology ; Endothelial Cells/*physiology ; Monocytes/*physiology ; Protein Kinase C beta/*metabolism; Animals ; CD40 Antigens/genetics ; CD40 Antigens/metabolism ; Cell Adhesion ; Cell Line ; Coculture Techniques ; Endothelium, Vascular/cytology ; Humans ; I-kappa B Proteins/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; NF-KappaB Inhibitor alpha ; Phosphorylation ; Protein Processing, Post-Translational ; Transcription Factor RelA/metabolism ; Vascular Cell Adhesion Molecule-1/metabolism
    • Abstract:
      Accumulating evidence supports the early involvement of monocyte/macrophage recruitment to activated endothelial cells by leukocyte adhesion molecules during atherogenesis. CD40 and its ligand CD40L are highly expressed in vascular endothelial cells, but its impact on monocyte adhesion and the related molecular mechanisms are not fully understood. The present study was designed to evaluate the direct effect of CD40L on monocytic cell adhesion and gain mechanistic insight into the signaling coupling CD40L function to the proinflammatory response. Exposure of cultured human aortic endothelial cells (HAECs) to clinically relevant concentrations of CD40L (20 to 80 ng/mL) dose-dependently increased human monocytic THP-1 cells to adhere to them under static condition. CD40L treatment induced the expression of vascular cell adhesion molecule-1 (VCAM-1) mRNA and protein expression in HAECs. Furthermore, exposure of HAECs to CD40L robustly increased the activation of protein kinase C beta (PKCβ) in ECs. A selective inhibitor of PKCβ prevented the rise in VCAM-1 and THP-1 cell adhesion to ECs. Moreover, stimulation of ECs to CD40L induced nuclear factor-κB (NF-κB) activation. PKCβ inhibition abolished CD40L-induced NF-κB activation, and NF-κB inhibition reduced expression of VCAM-1, each resulting in reduced THP-1 cell adhesion. Our findings provide the evidence that CD40L increases VCAM-1 expression in ECs by activating PKCβ and NF-κB, suggesting a novel mechanism for EC activation. Finally, administration of CD40L resulted in PKCβ activation, increased VCAM-1 expression and activated monocytes adhesiveness to HAECs, processes attenuated by PKCβ inhibitor. Therefore, CD40L may contribute directly to atherogenesis by activating ECs and recruiting monocytes to them.
    • Comments:
      Retraction in: PLoS One. 2023 Dec 5;18(12):e0295636. (PMID: 38051709)
    • References:
      Circulation. 2006 Feb 7;113(5):691-700. (PMID: 16461842)
      EMBO J. 2002 Dec 2;21(23):6539-48. (PMID: 12456660)
      Nat Rev Immunol. 2006 Jul;6(7):508-19. (PMID: 16778830)
      Circ Res. 2007 Aug 3;101(3):234-47. (PMID: 17673684)
      J Biochem Biophys Methods. 2004 Jul 30;60(1):23-7. (PMID: 15236907)
      N Engl J Med. 1999 Jan 14;340(2):115-26. (PMID: 9887164)
      Circ Res. 2001 Dec 7;89(12):1092-103. (PMID: 11739273)
      EMBO J. 2007 Feb 21;26(4):1150-62. (PMID: 17268554)
      Circulation. 2004 Jul 6;110(1):91-6. (PMID: 15210597)
      Atherosclerosis. 1998 Apr;137 Suppl:S89-95. (PMID: 9694547)
      Circulation. 1999 Aug 10;100(6):614-20. (PMID: 10441098)
      Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2897-908. (PMID: 21940946)
      Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1931-6. (PMID: 9050882)
      J Biol Chem. 1996 Jul 26;271(30):18068-73. (PMID: 8663499)
      Diabetes. 1998 Jun;47(6):859-66. (PMID: 9604860)
      Circ Res. 2002 Aug 9;91(3):263-71. (PMID: 12169653)
      Circulation. 2008 Feb 19;117(7):952-62. (PMID: 18250273)
      Circulation. 2001 Nov 6;104(19):2266-8. (PMID: 11696462)
      Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2292-301. (PMID: 17673705)
      J Exp Med. 2005 Nov 21;202(10):1423-31. (PMID: 16301747)
      Proc Natl Acad Sci U S A. 1995 May 9;92(10):4342-6. (PMID: 7538666)
      Circulation. 2001 Nov 13;104(20):2395-400. (PMID: 11705814)
      Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):6930-2. (PMID: 10860949)
      Nature. 1998 Feb 5;391(6667):591-4. (PMID: 9468137)
      N Engl J Med. 2003 Mar 20;348(12):1104-11. (PMID: 12646667)
      Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):519-24. (PMID: 17158355)
      Arterioscler Thromb. 1993 Feb;13(2):197-204. (PMID: 7678986)
      Anal Bioanal Chem. 2005 Mar;381(6):1138-44. (PMID: 15761741)
    • Accession Number:
      0 (CD40 Antigens)
      0 (I-kappa B Proteins)
      0 (NFKBIA protein, human)
      0 (Nfkbia protein, mouse)
      0 (RELA protein, human)
      0 (Transcription Factor RelA)
      0 (Vascular Cell Adhesion Molecule-1)
      139874-52-5 (NF-KappaB Inhibitor alpha)
      147205-72-9 (CD40 Ligand)
      EC 2.7.11.13 (Protein Kinase C beta)
    • Publication Date:
      Date Created: 20130917 Date Completed: 20140610 Latest Revision: 20231205
    • Publication Date:
      20231205
    • Accession Number:
      PMC3767684
    • Accession Number:
      10.1371/journal.pone.0072593
    • Accession Number:
      24039784